Companies
NVO
NOVO NORDISK A S
Novo Nordisk is a global healthcare company with commercial-stage products in obesity and diabetes care, including GLP-1 receptor agonists Wegovy and Saxenda in injectable formats plus Wegovy Pill, small molecule therapies, and modern and human insulins, alongside a rare disease portfolio of growth hormone and haemophilia products. The company markets Ozempic for type 2 diabetes and has achieved significant revenue growth in obesity treatment, with Wegovy generating DKK 79 billion in its fifth year post-launch across multiple geographic markets.
$42.22-33.56%1Y
NVO · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 3Cardiovascular Disease
Phase 3Type 2 Diabetes
Phase 3Diabetes Mellitus, Type 2
Phase 3Obesity
Phase 2Diabetes Mellitus, Type 2
Phase 2Diabetic Peripheral Neuropathy
Phase 3Obesity
Phase 3Haemophilia A With Inhibitors
Phase 3Haemophilia B With Inhibitors
Phase 3Haemophilia A Without Inhibitors
Phase 3Haemophilia B Without Inhibitors
Phase 3Haemophilia A and B With and Without Inhibitors
Phase 3Sickle Cell Disease
Phase 3Diabetes Mellitus, Type 1
Phase 3Diabetes Mellitus, Type 1
Phase 3Diabetes Mellitus, Type 1
Phase 3Obesity
Phase 3Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Phase 2Short Stature Children Born Small for Gestational Age (SGA)
Phase 3SGA, Turner Syndrome, Noonan Syndrome, ISS
Phase 3Type 2 Diabetes
Phase 3Non-alcoholic Steatohepatitis
Phase 3Obesity
Phase 3Cardiovascular Disease
Phase 3Diabetes Mellitus, Type 2
Phase 2Chronic Kidney Disease
Phase 3SGA
Phase 3Turner Syndrome
Phase 3Noonan Syndrome
Phase 3ISS
Phase 2Short Stature Children Born Small for Gestational Age (SGA)
Phase 3SGA, Turner Syndrome, Noonan Syndrome, ISS
Phase 3Diabetes Mellitus, Type 2
Phase 3Cardiovascular Risk
Phase 3Acute Myocardial Infarction (AMI)
Phase 3Heart Failure
Phase 3Myocardial Infarction
Phase 3Systemic Inflammation
Phase 2Heart Failure
Phase 2Chronic Kidney Disease
Phase 2Obesity
Phase 2Obesity
Catalyst Calendar
No catalyst events on record for yet. Check back after the next daily ingest.